skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treatment of phantom bite syndrome with milnacipran - a case series

(2403) Views  (502) Full article downloads

Authors: Akira Toyofuku, Toshihiro Kikuta

Published Date October 2006 Volume 2006:2(3) Pages 387 - 390
DOI: http://dx.doi.org/10.2147/NDT.S

Akira Toyofuku, Toshihiro Kikuta

 

Department of Dentistry and Oral Surgery, School of Medicine, Fukuoka University, Fukuoka, Japan

 

Abstract: Phantom bite syndrome is characterized by an uncomfortable sensation mainly affecting corrected dentition in which no abnormality is clinically detectable. Despite repeated failures of dental surgery, sufferers persist in seeking bite correction from a succession of dentists. The etiology–pathogenesis of phantom bite is unknown but some consider the syndrome to be a psychosomatic disorder. Seven patients with this syndrome were treated with the serotonin and norepinephrine reuptake inhibitor milnacipran for 4 weeks. One patient withdrew after 2 weeks because he was feeling “well”. At the end of the study, 5 of the 6 patients completing the study reported significant improvements, with a mean decrease in occlusal discomfort of 55.3%, as indicated by a visual analogue scale. This result appeared to be independent of any antidepressant effect. Only minor and transient side-effects were observed. It is suggested that milnacipran may be a helpful treatment for phantom bite but this needs to be confirmed by further and longer term studies.

 

Keywords: phantom bite syndrome, occlusal discomfort milnacipran oral psychosomatic disorders








Readers of this article also read:

Prophylaxis of migraine
The use of combination therapies in the acute management of migraine
Religiosity in patients with Parkinson's disease
Editorial: Migraine – a suitable case for treatment? || FREE PAPER ||
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
Balancing false discovery and false negative rates in selection of differentially expressed genes in microarrays
Hyperbaric oxygen ameliorates worsening signs and symptoms of post-traumatic stress disorder
Errantum: Treatment of human astrocytoma U87 cells with silicon dioxide nanoparticles lowers their survival and alters their expression of mitochondrial and cell signaling proteins
Update on the role of antipsychotics in the treatment of Tourette syndrome